By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


Start Up


Dyax  Antibody phage display

Company News
Merrimack (MACK) Announces Timing Of First Quarter 2016 Investor Conference Call 4/21/2016 6:38:32 AM
Merrimack (MACK) Unveils Its Latest Antibody Directed Nanotherapeutic, MM-310, At The 2016 AACR Annual Meeting 4/21/2016 6:30:05 AM
Leica Biosystems And Merrimack (MACK) To Collaborate On Development Of A Heregulin Companion Diagnostic For Seribantumab 4/15/2016 6:13:42 AM
Merrimack (MACK) Announces Inclusion of ONIVYDE (Irinotecan Liposome Injection) As A Category 1 Treatment Option In The 2016 NCCN Guidelines For Pancreatic Adenocarcinoma 3/24/2016 12:27:30 PM
Merrimack (MACK) To Present On Multiple Oncology Programs At The 2016 AACR Annual Meeting 3/17/2016 7:26:55 AM
Merrimack (MACK) Reports Fourth Quarter 2015 Financial Results 2/26/2016 6:36:58 AM
Merrimack (MACK) Announces Timing Of Fourth Quarter 2015 Investor Conference Call 2/17/2016 7:02:08 AM
Merrimack (MACK) Release: Updated Data Shows ONIVYDE (irinotecan liposome injection) Combination Regimen Increased One Year Survival By 63% In Patients With Metastatic Pancreatic Cancer 1/20/2016 5:57:48 AM
Merrimack (MACK) To Present Updated Overall Survival Analysis Of Phase 3 NAPOLI-1 Study Of ONIVYDE (irinotecan liposome injection) At The ASCO 2016 Gastrointestinal Cancers Symposium 1/11/2016 6:26:36 AM
Merrimack (MACK) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/5/2016 10:02:47 AM